BMY vs. REGN: Bristol-Myers Squibb vs. Regeneron Pharmaceuticals Stock Comparison

Company Profile

Bristol-Myers Squibb (BMY) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMY is classified in Pharmaceuticals while REGN is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Bristol-Myers Squibb (BMY) is heavily traded at around 10.85M shares per day, whereas Regeneron Pharmaceuticals (REGN) sees a more moderate 772.95K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bristol-Myers Squibb (BMY) at 44.01% and Regeneron Pharmaceuticals (REGN) at 14.95% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bristol-Myers Squibb (BMY) at 18.47% and Regeneron Pharmaceuticals (REGN) at 28.51% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Bristol-Myers Squibb (BMY) at 33.79% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Bristol-Myers Squibb (BMY) at -0.22% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Bristol-Myers Squibb (BMY) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Bristol-Myers Squibb (BMY) at 1.59 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMY.

Regeneron Pharmaceuticals (REGN) at 0.08 is near its industry mid-range for debt-to-equity ratio, while Bristol-Myers Squibb (BMY) at 1.91 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Bristol-Myers Squibb (BMY) at 3.99% and Regeneron Pharmaceuticals (REGN) at 0.41% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Bristol-Myers Squibb (BMY) at 55.88% and Regeneron Pharmaceuticals (REGN) at 8.18% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Both Bristol-Myers Squibb (BMY) at 13.78 and Regeneron Pharmaceuticals (REGN) at 19.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while Regeneron Pharmaceuticals (REGN) at 5.54 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Bristol-Myers Squibb (BMY) at 5.43 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics